Syndax Pharmaceuticals, Inc. (SNDX)
19.29
-0.25
(-1.28%)
USD |
NASDAQ |
Aug 31, 16:00
19.34
+0.05
(+0.26%)
After-Hours: 20:00
Syndax Pharmaceuticals Free Cash Flow : -220.87M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -220.87M |
| March 31, 2026 | -278.35M |
| December 31, 2025 | -323.17M |
| September 30, 2025 | -311.01M |
| June 30, 2025 | -302.67M |
| March 31, 2025 | -286.52M |
| December 31, 2024 | -274.90M |
| September 30, 2024 | -258.86M |
| June 30, 2024 | -241.20M |
| March 31, 2024 | -204.92M |
| December 31, 2023 | -160.60M |
| September 30, 2023 | -142.15M |
| June 30, 2023 | -126.04M |
| March 31, 2023 | -130.97M |
| December 31, 2022 | -133.68M |
| September 30, 2022 | -10.20M |
| June 30, 2022 | -6.601M |
| March 31, 2022 | 9.66M |
| December 31, 2021 | 29.00M |
| September 30, 2021 | -87.21M |
| June 30, 2021 | -80.56M |
| March 31, 2021 | -77.92M |
| Date | Value |
|---|---|
| December 31, 2020 | -71.26M |
| September 30, 2020 | -68.36M |
| June 30, 2020 | -58.59M |
| March 31, 2020 | -49.71M |
| December 31, 2019 | -50.61M |
| September 30, 2019 | -52.94M |
| June 30, 2019 | -62.88M |
| March 31, 2019 | -65.51M |
| December 31, 2018 | -68.72M |
| September 30, 2018 | -66.42M |
| June 30, 2018 | -58.18M |
| March 31, 2018 | -54.83M |
| December 31, 2017 | -47.46M |
| September 30, 2017 | -45.11M |
| June 30, 2017 | -46.39M |
| March 31, 2017 | -41.55M |
| December 31, 2016 | -35.42M |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| September 30, 2014 | -13.70M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Viking Therapeutics, Inc. | -418.44M |
| Kura Oncology, Inc. | -117.43M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -30.27M |
| Cash from Investing (Quarterly) | -16.91M |
| Cash from Financing (Quarterly) | 252.77M |
| Free Cash Flow Per Share (Quarterly) | -0.3406 |
| Free Cash Flow to Equity (Quarterly) | -274.33M |
| Free Cash Flow to Firm (Quarterly) | -17.64M |
| Free Cash Flow Yield | -13.04% |